

**Oral Poster Presentation 1 [Autoimmune Disease]**

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP01	307	Epidemiological trends of autoimmune hepatitis in South Korea: a population-based study from 2010 to 2023	Kyung-Ah Kim	Inje University
16:50-17:00	OP02	683	Epidemiology, Treatment Response, and Genetic Characteristics of Autoimmune Liver Diseases: A Retrospective and Prospective Cohort Study	Young Chang	Soonchunhyang University
17:00-17:10	OP03	109	A novel risk prediction model for survival in patients with autoimmune hepatitis: a multicenter cohort study	Soon Kyu Lee	The Catholic University of Korea
17:10-17:20	OP04	532	Clinical statement for the diagnosis and management of PBC-AIH overlap 2024: Japanese experience	Atsumasa Komori	NHO Nagasaki Medical Center, Japan
17:20-17:30	OP05	279	Intrahepatic infiltration of activated Regulatory T cells is associated with the degree of inflammation in Autoimmune hepatitis	Mi Hyun Kwon	The Catholic University of Korea
17:30-17:40	OP06	756	Post-Transplant Outcomes in Primary Sclerosing Cholangitis Patients: A Case Series Focusing on Ulcerative Colitis Associated Complications	Min Kyoung Kim	Seoul National University

**Oral Poster Presentation 2 [MASLD & ALD, Basic]**

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP07	357	Liver Kinome Profiling Identifies PS1145-IKK Inhibition as a Potential Therapeutic Strategy for Systemic Inflammation in Alcohol-Associated Liver Diseases	MANISHA YADAV	Institute of Liver and Biliary sciences, India
16:50-17:00	OP08	192	Adenosine triphosphate-binding pocket inhibitor for mixed lineage kinase domain-like protein attenuated alcoholic liver disease via necroptosis-independent pathway	Seung Min Lee	Hanyang University
17:00-17:10	OP09	33	Polyethylene glycol relieves hangover symptoms and protects liver and gut by preventing intestinal absorption of alcohol	Keungmo Yang	The Catholic University of Korea
17:10-17:20	OP10	217	GINS2 Accelerated Non-Alcoholic Fatty Liver Disease via Regulating TFEB Mediated Lipophagy	Zhaohong Mo	Guangxi Medical University, China
17:20-17:30	OP11	193	Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis	Hye Young Kim	Hanyang University
17:30-17:40	OP12	172	Treatment with IL-18 binding protein biologics inhibits fibrotic progression in metabolic dysfunction-associated steatohepatitis.	Dong-Hyun Kim	Kangwon National University

**Oral Poster Presentation 3 [MASLD, Clinical 1]**

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP13	200	Improvement of Hepatic Steatosis and Reduction in Cardiovascular Event in Patients with Diabetes Mellitus: A Prospective Study	Yoon Seok Lee	Gachon University
16:50-17:00	OP14	93	Association between Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Eosinophilic Esophagitis (EOE): A Retrospective Cohort Analysis of the Multicenter Research Network Study in the United States	Rishi Chowdhary	MetroHealth Medical Center, USA
17:00-17:10	OP15	62	Higher Age-Adjusted Skeletal Muscle Index Associated with Severe Hepatic Steatosis and Fibrosis in male MASLD Patients	JungHee Kim	Hallym university
17:10-17:20	OP16	492	Effect of vitamin E on liver stiffness in metabolic dysfunction-associated steatotic liver disease	Seung Teak Lee	Seoul National University
17:20-17:30	OP17	174	Changing Prevalence and Risks Factors of Metabolic dysfunction Associated Steatotic Liver Disease during three decades in Taiwan	Ming-Lun Yeh	National Sun Yat-sen University, Taiwan
17:30-17:40	OP18	69	Association Between Smoking and Clinical Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease	Tom Ryu	Soonchunhyang University

#### Oral Poster Presentation 4 [LC, Clinical & Liver Failure]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP19	194	Impact of Cardiometabolic Risk Factors on Hepatic Fibrosis and Clinical Outcomes in MASLD: A Population-based Multi-Cohort Study	Eileen Laurel Yoon	Hanyang University
16:50-17:00	OP20	687	A prospective multicenter study for comparison of standard dose repeated bolus injection vs. low dose continuous intravenous infusion of terlipressin for acute esophageal variceal bleeding in patients with liver cirrhosis	Hyung Joon Yim	Korea University
17:00-17:10	OP21	495	Spleen Stiffness Measurement using New Spleen-Dedicated Fibroscan: Intra/Interobserver Repeatability	Heon-Ju Kwon	Sungkyunkwan University
17:10-17:20	OP22	111	Validation and Comparative Performance of Postoperative Risk Scores in Cirrhotic Patients: A Korean Cohort Study	Hee Sun Cho	The Catholic University of Korea
17:20-17:30	OP23	331	Identifying Low-Risk Patients with Cirrhosis and Acute Gastrointestinal Bleeding that may not require Emergency Endoscopy	Sijia Zhang	General Hospital of Northern Theater Command , China
17:30-17:40	OP24	104	Impact of Hepatic Encephalopathy on Prognosis in Cirrhotic Patients with Acute Decompensation: The Crucial Role of Underlying Liver Function and Coagulation Failure	Junghee Kim	Hallym university

#### Oral Poster Presentation 5 [Liver Transplantation 1]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP25	568	Renal Recovery Benefit of Living Donor Compared to Deceased Donor Liver Transplantation in High-MELD Recipients: A Propensity Score-Matched Study	Sung-Min Kim	University of Ulsan
16:50-17:00	OP26	668	Machine Perfusion in Marginal Liver Grafts: A Systematic Review of Clinical Impact on Liver Transplantation	Lok Ranjan Rajmohan	ACS Medical College and Hospital,India
17:00-17:10	OP27	187	Liver transplantation can be a treatment option for patients with cholangiocarcinoma: A Single-Center Experience	Youngju Ryu	Sungkyunkwan University
17:10-17:20	OP28	398	BILE DUCT COMPLICATION AND IMPACT ON OUTCOMES AFTER LIVING-DONOR LIVER TRANSPLANT: A MACHINE LEARNING APPROACH	Derizal Derizal	Ip Trisakti, Indonesia
17:20-17:30	OP29	715	Impact of Radiation Therapy on Biliary Complications in Liver Transplant Hepatocellular Carcinoma Recipients Withoma: A Propensity Score-Matched Analysis	Min-Ha CHOI	University of Ulsan
17:30-17:40	OP30	125	Xenotransplantation of Pancreatic Islet Cells: A Promising Approach for Type 1 Diabetes Treatment	Nodirjon Ruzimurodov	Institute of Immunology and Human Genomics of the Academy of Science of the Republic of

#### Oral Poster Presentation 6 [Liver Cancer, Basic 1]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP31	296	Identification of IKBKB as a Novel Regulator of Macrophage Phagocytosis That Enhances Antitumor Immunity in Hepatocellular Carcinoma	Sze Man CHAN	The Hong Kong Polytechnic University, Hong Kong
16:50-17:00	OP32	431	Identifying the key factors contributing to the progress of liver fibrosis to cancer and the tumor microenvironment immunosuppression	HONGPING XIA	Southeast University, China
17:00-17:10	OP33	534	Inhibition of PLD1 Increases Apoptosis in Hepatocellular Carcinoma Cells	Ha Neul Kim	Chungnam National University
17:10-17:20	OP34	727	Genomic Analysis of Combined Hepatocellular-Cholangiocarcinoma Reveals Common Lineage of Tumor Components with Unique Gene Expression Profile	Yeshong PARK	Seoul National University
17:20-17:30	OP35	20	CRY2 is an actionable target to modulate tumor growth and stemness in hepatocellular carcinoma	Regina Lo	The University of Hong Kong, Hong Kong
17:30-17:40	OP36	116	PNPLA3 I148M GG Variant Correlates with Poor Tumor Differentiation but Not HCC Risk in MASLD Patients	Jaejun Lee	The Catholic University of Korea

#### Oral Poster Presentation 7 [Liver Cancer, Clinical 1]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP37	139	A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab: the MAGIC-D index.	Mara Persano	IRCCS San Raffaele, India
16:50-17:00	OP38	545	Mass Spectrometry-Based Proteomics Analysis to Discover Biomarkers in Atezolizumab and Bevacizumab Therapy for Patients with Advanced Hepatocellular Carcinoma	Eunho Choi	Korea University
17:00-17:10	OP39	243	Development and Validation of a Risk Prediction Model for Patients with Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab	Heechul Nam	The Catholic University of Korea
17:10-17:20	OP40	519	Prognostic Impact of Diabetes and Hypertension on Hepatocellular Carcinoma Survival: A 15-Year Registry-Based Analysis	Hyeyeon Hong	University of Ulsan
17:20-17:30	OP41	432	Machine Learning-Based Prediction of Clinically Significant Portal Hypertension and Future Hepatic Decompensation in Patients with BCLC-C hepatocellular carcinoma	Ji Won Han	The Catholic University of Korea
17:30-17:40	OP42	573	Bleeding Complications and Survival Outcomes in HCC Patients Treated with Atezolizumab/Bevacizumab.: Multicenter Real-World study	Yu Rim Lee	Kyungpook National University

### Oral Poster Presentation 8 [Liver Cancer, Clinical 2]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP43	135	Clinical characteristics and outcome of patients with Fibrolamellar Hepatocellular carcinoma: an analysis of a large population using real-world data	Federica Lo Prinzi	Campus Bio-medico, Italy
16:50-17:00	OP44	355	The Role of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma in The Era of Immune Checkpoint Inhibitor	Kyungdeok Bae	University of Ulsan
17:00-17:10	OP45	21	15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry	Jonggi Choi	University of Ulsan
17:10-17:20	OP46	572	Impact of endoscopic retrograde cholangiopancreatography and radiation therapy in hepatocellular carcinoma patients with bile duct invasion receiving atezolizumab plus bevacizumab	Kiyoun Yi	Pusan National University
17:20-17:30	OP47	579	RT combination in Atezolizumab and Bevacizumab Benefits Hepatocellular Carcinoma with HBV Etiology	Kwon Yong Tak	The Catholic University of Korea
17:30-17:40	OP48	552	Decision Tree Modeling of Exosomal miR-30a-5p for Predicting Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma	Eunho Choi	Korea University

### Oral Poster Presentation 9 [Liver Surgery]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP49	701	Divergent Impact of Preoperative Platelet Count Abnormalities on Long-Term Outcomes after Curative Hepatic Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis of 3,116 Patients	Tian YANG	Naval Medical University, China
16:50-17:00	OP50	695	Superior Prognostic Performance of the AFP Model Over Milan Criteria Following Hepatic Resection for Hepatocellular Carcinoma: A Multi-Institutional Analysis	Chao LI	Naval Medical University, China
17:00-17:10	OP51	698	Development and Validation of a Laboratory Risk Score (APASL Score) to Predict Long-Term Survival after Hepatectomy for Hepatocellular Carcinoma: A Multicenter Analysis	Bai-Dong WANG	Basic Medical College, China
17:10-17:20	OP52	725	Laparoscopic Right Anterior or Posterior Sectionectomy for HCC: Surgical Outcomes Based on Surgeon's Learning Curve	Su Hyeong PARK	Catholic Kwandong University
17:20-17:30	OP53	767	Caregiver Perception, Knowledge, and Attitude toward Postoperative Recovery among Patients with Liver Disease	Lintong Hottua SIMBOLON	The Pranala Institute, Indonesia
17:30-17:40	OP54	75	Surgical approach to supradiaphragmatic IVC tumor thrombosis of HCC through abdominal cavity by cutting diaphragm vertically without opening the pericardium	Nyamsuren Ganbileg	National Cancer Center of Mongolia, Mongolia

### Oral Poster Presentation 10 [Liver Cancer, Basic 2]

Time	Abstract No.		Subject	Presenting Author	Institution
16:40-16:50	OP55	685	Focal Amplification of EGFR Drives Acquired Resistance to Lenvatinib in Hepatocellular Carcinoma	Ji Young Kim	Sungkyunkwan University
16:50-17:00	OP56	328	A study on the Development of a Traditional Liver Cancer Mouse Model Using Hydrodynamic injection	HyeonJi Kim	Kyungpook National University
17:00-17:10	OP57	233	Prolonged lenvatinib treatment affects tumor-neutrophil interaction and contributes to compromised immune checkpoint blockade treatment in hepatocellular carcinoma	Yunong Xie	The Chinese University of Hong Kong, Hong Kong
17:10-17:20	OP58	270	IGF2BP1 promotes proliferation and metastasis of hepatocellular carcinoma via m6A-modified PEG10 mRNA	Qiongguang Huang	Guangxi Medical University, China.
17:20-17:30	OP59	321	Finding the role of a novel oncogene in liver cancer through hydrodynamic gene delivery	Ha Gyun Kim	Kyungpook National University
17:30-17:40	OP60	90	Long non-coding RNA TUG1 regulates multiple glycolytic enzymes in hepatocellular carcinoma cells via sponging microRNA-122-5p	Chaiyaboot Ariyachet	Chulalongkorn University, Thailand



### Oral Poster Session [DAY 3: May 31, 2025 | 09:30-10:30]

### Oral Poster Presentation 11 [HBV]

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP61	159	Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Insights from Nationwide Cohort Study	Hyun Bin Choi	Soonchunhyang University
09:40-09:50	OP62	82	VELLIA®(DA-2803) versus VELMIDY® for the Treatment of Patients with Chronic Hepatitis B: a Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority Study	Jeayeon Park	Seoul National University
09:50-10:00	OP63	128	Comparative Risk of Osteoporosis and Fractures in Chronic Hepatitis B Patients: Tenofovir Disoproxil Fumarate versus Entecavir in a Korean Nationwide Cohort	Jisoo Lee	Soonchunhyang University
10:00-10:10	OP64	333	Turning LLMs into Clinical Decision Supporters: Optimizing Prompt Structures for Drug Side Effect Prediction in Chronic Hepatitis B Patients	Jihyun Moon	Handong Global University
10:10-10:20	OP65	138	Longitudinal renal function trajectories in chronic hepatitis B patients on entecavir or tenofovir alafenamide: A nationwide population-based study in Korea	Jae Hyun Yoon	Chonnam National University
10:20-10:30	OP66	115	Efficacy of Prophylactic Antiviral Therapy in Preventing Hepatitis B Reactivation in Patients with Anti-HBc Antibody Undergoing Daratumumab Treatment	Jaejun Lee	The Catholic University of Korea

### Oral Poster Presentation 12 [MASLD, Clinical 2]

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP67	575	Intermittent Calorie Restriction Modulates Gut Microbiota in patients with MASLD without diabetes	Han Ah Lee	Chung-Ang University
09:40-09:50	OP68	383	A Randomized Controlled Trial to Explore the Effect of Modulation of Gut Microbiota on Liver Fibrosis in Patients with Non-Alcoholic Steatohepatitis	Fayaz Ahmed Mubarak Ali	Guwahati Medical College and Hospital, India
09:50-10:00	OP69	389	Impaired sensitivity to thyroid hormones is associated with cardiovascular outcomes in Euthyroid subjects with metabolic dysfunction-associated steatotic liver disease	Yeonjung Ha	CHA University
10:00-10:10	OP70	292	Cancer Risk and Its Non-Invasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis	Hana Park	University of Ulsan
10:10-10:20	OP71	468	Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis	Min Kyung Park	Seoul National University
10:20-10:30	OP72	426	PNPLA3 p.I148M Polymorphism Increases Risk of Liver Fibrosis in Breast Cancer Patients Receiving Tamoxifen Therapy	Sangdeok Shin	Sungkyunkwan University

### Oral Poster Presentation 13 [Liver Cancer, Clinical 3]

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP73	310	Impact of metformin administration on clinical outcomes in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab	Yonseok Lee	Gachon University
09:40-09:50	OP74	591	Midterm Outcomes and Characteristics of Pseudoprogression in HCC Following First-Line Atezolizumab-Bevacizumab Therapy	Kyowon Gu	Sungkyunkwan University
09:50-10:00	OP75	158	Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients With Early-Stage Hepatocellular Carcinoma	Dong Hyun Kim	Yonsei University
10:00-10:10	OP76	578	Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma	Dong Hwan Kim	University of Ulsan
10:10-10:20	OP77	483	Association Between Young Age and Prognosis of Hepatocellular Carcinoma: A Large Single-Center Matched Study	Sang-Hoon Kim	University of Ulsan
10:20-10:30	OP78	797	Real-World Incidence and Predictive Factors of Variceal Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab	Jeong Eun Song	Daegu Catholic University

### Oral Poster Presentation 14 [HBV& LC, Basic]

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP79	480	Liver on the Mend: CRISPR-Based Gene Therapy as a Game-Changer for Genetic Hepatic Diseases	GAYATHRI SARAVANAN	ACS Medical College and Hospital, India
09:40-09:50	OP80	625	In Silico Design and Evaluation of siRNA Targeting HBV S and C Genes for Hepatitis B Treatment	Reny Rosalina	Universitas Palangka Raya, Indonesia
09:50-10:00	OP81	634	cccDNA as a Therapeutic Target in Hepatitis B Virus Infection: Mechanisms and Drug Development - A Systematic Review	Lok Ranjan Rajmohan	ACS Medical College and Hospital, India
10:00-10:10	OP82	362	In patients with hepatocellular carcinoma, autologous NK cell immunotherapy after transarterial-chemoembolization (TACE) increased disease-free survival and improved liver fibrosis: proof of concept study	JooHo Lee	CHA University
10:10-10:20	OP83	204	Intrahepatic B Cells Aggravate Liver Fibrosis by Producing Pro-fibrotic Mediators through CD40-mediated NKT Interaction	Jihyo Byun	KAIST
10:20-10:30	OP84	312	Verification of Liver Sinusoid Endothelial Cell Normalization and Hepatic Progenitor Cell Activation Efficacy of Bone Marrow- Mesenchymal Stem Cell derived Extracellular Vesicles	Mi Ra Lee	Yonsei University Wonju

### Oral Poster Presentation 15 [Others]

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP85	598	ROS mediated HMGB1-RIPK1 upregulation mediates hepatocellular injury, inflammation promotes endothelial dysfunction and ductal proliferation in Drug induced Liver Injury	Himanshi	Institute of Liver and Biliary Sciences, India
09:40-09:50	OP86	228	STRAP promotes drug-induced acute liver injury via mTOR-mediated autophagy	Mingbei Zhong	Guangxi Medical University, China
09:50-10:00	OP87	198	3D Bioprinted Tubular Hepatobiliary Model Enabling Bile Acid Transport and Drainage	Seon-Jin Kim	Pohang University of Science and Technology
10:00-10:10	OP88	229	"Targeting Hepatic Stem Cell Niche with Epigenetic Modulators for Accelerated Liver Regeneration in Advanced Hepatic Fibrosis"	VENKATAKRISHNAN KARUNANITHI	ACS Medical College and Hospital, India
10:10-10:20	OP89	368	A Prospective cohort study of Hepatic and biliary Complications in pediatric patients with Sickle Cell Disease in India.	DR. ASHISHKUMAR CHAUDHARI	GMERS MEDICAL COLLEGE VALSAD, India
10:20-10:30	OP90	622	The effectiveness of addominal doppler ultrasound, measurement of abdominal fat, and the value of SWM/ATT in the assessment of liver disease	Soung Won Jeong	Soonchunhyang University

**Oral Poster Presentation 16 [Liver Cancer, Clinical 4]**

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP91	612	Comparative effectiveness of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Hepatocellular Carcinoma Recurrence and Mortality After Curative Treatment	Ji Eun Han	Ajou University
09:40-09:50	OP92	215	The Role of TARE for bridging and downstaging of HCC before resection or liver transplant: A Retrospective	ABDULLAH ALSHAMRANI	Sungkyunkwan University
09:50-10:00	OP93	584	Proteinuria and Its Clinical Implications in HCC Patients Treated with Atezolizumab/Bevacizumab: A Multicenter Real-World study	Yu Rim Lee	Kyungpook National University
10:00-10:10	OP94	214	Metastatic Patterns and Their Clinical Implications in Hepatocellular Carcinoma: Analysis of a Nationwide Korean Cancer Registry	HA IL KIM	Hanyang University
10:10-10:20	OP95	242	The Real Change in cholangiocarcinoma? A Real World Experience	Stefano Mariani	A.O.U. Cagliari, Italy
10:20-10:30	OP96	724	Efficacy of Lymphadenectomy in Intrahepatic Cholangiocarcinoma	In Soo CHO	Keimyung University

**Oral Poster Presentation 17 [Liver Transplantation 2]**

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP97	785	Clinical Significance of De Novo Malignancy after Liver Transplant: Update on a Single-Center Study	Jae-Yoon KIM	Seoul National University
09:40-09:50	OP98	30	Investigating Key Factors of Fatty Liver Disease in Liver Donors	E. Ben George	University of Technology and Applied Sciences - Muscat, Oman
09:50-10:00	OP99	759	ABO Incompatible Dual Graft Living Donor Liver Transplantation Using Modified Extended Left Lateral Graft: Case Report	Dae Hyeon WON	University of Ulsan
10:00-10:10	OP100	168	Ameliorating effect of curcumin loaded silver nanoparticles against liver transplantation associated ischemia-reperfusion injury by downregulating inflammation and TLR-4/NF-κB/NLRP3 signalling pathway	Ekta Yadav	SHUATS, India
10:10-10:20	OP101	754	Outcomes and Risk Factors for De Novo Major Depressive Disorder after Liver Transplantation: Nested Case-Control Study	Young Jin YOO	Yonsei University
10:20-10:30	OP102	10	Comparison of effectiveness of mycophenolate mofetil associated with standard dosaged or reduced-dose tacrolimus for liver transplantation immunosuppression	Ulil Albab Habibah	Islamic University, Indonesia

**Oral Poster Presentation 18 [Liver Cancer, Basic 3]**

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP103	183	Characterization of diverse extracellular nanoparticles and tumorigenic relevance in hepatocellular carcinoma	Charlotte Jiaqi LAI	University of Hong Kong, Hong Kong
09:40-09:50	OP104	94	Spatial Transcriptomics Uncovers Intratumoral Molecular Heterogeneity in Hepatoblastoma	In Hye Song	University of Ulsan
09:50-10:00	OP105	185	Differential infiltration of T-cell populations in tumor and liver tissue predicts recurrence-free survival in surgically resected hepatocellular carcinoma	Eun Ji Jang	The Catholic University of Korea
10:00-10:10	OP106	531	Visceral adipose tissue from morbid obesity patients promotes the proliferation of hepatocellular carcinoma cells	Ji Yeon Park	Keimyung University
10:10-10:20	OP107	78	CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications	Se Ha Jang	Ajou University
10:20-10:30	OP108	26	RBBP7 Promotes Hepatocellular Carcinoma Progression via Enhancing Small Extracellular Vesicle Secretions	Wing Lam Tam	The University of Hong Kong, Hong Kong

**Oral Poster Presentation 19 [Liver Cancer, Clinical 5]**

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP109	436	Clinical outcomes of atezolizumab plus bevacizumab in viral and non-viral advanced HCC patients : A real-world, multicenter study	Yeo Wool Kang	Dong-A University
09:40-09:50	OP110	95	Comparative Prognostic Value of Albumin-Bilirubin Grade, PALBI, and MELD 3.0 in Hepatocellular Carcinoma Patients with Renal Insufficiency	Myeong Jun Song	The Catholic University of Korea
09:50-10:00	OP111	124	Machine Learning-Based Risk Stratification to Optimize Treatment Selection Between Surgical Resection and Liver Transplantation	Hyun Uk Kim	The Catholic University of Korea
10:00-10:10	OP112	554	Clinical Outcomes of 2,000 Hepatocellular Carcinoma Patients Treated with Proton Beam Therapy at Single Center: Toward Further Optimized Treatment Strategies	Jeong Ha Lee	Sungkyunkwan University
10:10-10:20	OP113	718	Beliefs about Anatomical Liver Resection: Does Anatomical Liver Resection Always Ensure Adequate Surgical Margins?	Boram LEE	Seoul National University
10:20-10:30	OP114	265	Liver Resection in Stage 0-A HCC in Segments 7/8: A Propensity-Matched Analysis Comparing Open, Laparoscopic, and Robotic Approach	Yunchuan Wang	Guangxi Medical University, China

**Oral Poster Presentation 20 [Biliary and Pancreatic Surgery]**

Time	Abstract No.		Subject	Presenting Author	Institution
09:30-09:40	OP115	742	Robotic-Assisted Surgery for Complex Biliary Strictures: A Prospective Study	Pavithran DAMODARAN	ACS Medical College And Hospital, India
09:40-09:50	OP116	167	Effect of Head coring with Lateral pancreaticojejunostomy on Pancreatic exocrine function in patients with Idiopathic chronic pancreatitis – a prospective observational study	Kislay Kant	All India Institute of Medical Sciences, India
09:50-10:00	OP117	367	Robotic Parenchyma-Preserving Surgery for Hilar Cholangiocarcinoma: A Feasibility Analysis	Sasireka Veerasamy	JIPMER, India
10:00-10:10	OP118	470	Immediate results of laparoscopic spleen-preserving distal pancreatectomy: Kimura vs Warshaw operation.	Ilya Vervekin	Pavlov First Saint Petersburg State Medical University, Russia
10:10-10:20	OP119	592	Preoperative UGI Scopy: Reducing Post-Cholecystectomy Syndrome and Pain Severity	John Thomas Arul J S	ACS Medical College and Hospital, India
10:20-10:30	OP120	738	Comparison of Rectal Indomethacin with Placebo in Reducing the Clinical Progression of Mild and Moderate Acute Pancreatitis to Severe Acute Pancreatitis- A Double Blinded Randomized Controlled Trial	Raj Kumar NAGARAJAN	Jawaharlal Institute of Post Graduate Medical Education and Research(JIPMER), India







